Merck CEO To Street: Watch For Short-term Adaptability, Long-Term Innovation
This article was originally published in The Pink Sheet Daily
Executive Summary
Newly named chairman, Merck’s CEO Ken Frazier, cites several – smallish – launches, flexibility, especially in the face of setbacks, and business development, and ongoing focus on innovation as priorities in 2012 that will lead to long-term sustainability.
You may also be interested in...
A Changing Of The Guard At Merck R&D As Perlmutter Succeeds Kim
Amid growing concern over the quality of Merck’s late-stage pipeline, CEO Frazier made a decisive move to change the R&D leadership; Former Amgen R&D head Perlmutter will succeed Merck Research Laboratories President Kim in April.
A Changing Of The Guard At Merck R&D As Perlmutter Succeeds Kim
Amid growing concern over the quality of Merck’s late-stage pipeline, CEO Frazier made a decisive move to change the R&D leadership. Former Amgen R&D head Perlmutter will succeed Merck Research Laboratories President Kim in April.
Europe’s Newest Biotech – Valneva – Formed As Intercell And Vivalis Marry
One of the few remaining independent biotech vaccine developers in Europe, Austria's Intercell, is to join forces with France's Vivalis in a proposed merger valued at $174 million to create a pipeline spanning from antibodies to vaccines.